Larkspur Health Acquisition Corp

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It leverages advanced & proprietary technologies to develop product candidates in the areas of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

ZyVersa Therapeutics Inc

ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J.

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")

Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseases By inhibiting ASC, IC 100 inhibits multiple types of inflammasomes, not just NLRP3, to stop initiation of the inflammatory cascade and progression of damaging inflammation that is pathogenic in inflammatory diseases ZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 2022, which is expected to be completed in fourth quarter of 2022; combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA" WESTON, Fla. and BRIDGEWATER, N.J.

ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A.

Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting multiple renal diseases, and an inflammatory ASC inhibitor targeting numerous inflammatory diseases ZyVersa and Larkspur Health entered into a definitive business combination agreement dated July 20, 2022, as amended (the "Business Combination Agreement") Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ in fourth quarter of 2022 under ticker "ZVSA" BRIDGEWATER, N.J. and WESTON, Fla.

SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.

Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms targeting renal and inflammatory diseases ZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 2022, which is expected to be completed in fourth quarter of 2022 Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA" WESTON, Fla. and BRIDGEWATER, N.J.

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference

Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022 ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs in patients with renal and inflammatory diseases Transaction expected to be completed in fourth quarter of 2022 Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA" BRIDGEWATER, N.J. and WESTON, Fla.

ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update

Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases IC 100 research was conducted at the University of Miami Miller School of Medicine by acclaimed experts in immunology, and leaders at the forefront of inflammasome research IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes, including NLRP1, to block initiation and perpetuation of damaging chronic inflammation WESTON, Fla. and BRIDGEWATER, N.J.

Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging

Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics

IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation IC 100 has broad tissue distribution, including CNS and peripheral tissues, is rapidly internalized by a variety of cell types, binds to intracellular ASC blocking inflammasome activation, and binds to ASC specks altering ASC speck architecture and function WESTON, Fla. and BRIDGEWATER, N.J.

ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper

News for Larkspur Health Acquisition Corp Stock (LSPR)